ERBB2 and breast cancer: Collectively, 97 BC biosignatures have been reported so far from proteomics studies, including pathways related to ER, p53, CK8/18, Ki-67, PR, cyclin D1, HER-2, CK5/6, cyclin E, BCL2, cyclin E and E-cadherin [81].